Blogs | Multibagger Shares

May 4, 2026

Hero Header Announcing Walter Schlosss 16 Factors with a Two by two Grid of Panels Labeled Trader Compounder Drift and Speculator

Walter Schloss’s 16 Factors: How Graham’s Quietest Disciple Beat the Market for 47 Years Without Ever Meeting Management

Walter Schloss compounded 16% for 47 years from a back office, with no MBA, no Bloomberg terminal, and no management visits. Seven of his 16 factors illustrated through Titan Biotech FY25's audited balance sheet.

May 3, 2026

Hero Section with Title outside View Vs Inside View and Subtitle Below is a 2x2 Color Grid Labeled Top left lucky Top right discipined Investor Bottom left confused Bottom right bias trapped

Outside View vs Inside View: Kahneman & Lovallo’s Reference-Class Forecasting Discipline

Daniel Kahneman and Dan Lovallo's 1993 distinction between the Inside View (story-driven) and the Outside View (reference-class base rates) is the most powerful behavioural upgrade an Indian long-term investor can make. We illustrate it with Titan Biotech's FY25 audited numbers, presented strictly as an educational case study of management process — not a valuation call.

May 3, 2026

Infographic Titled beneish M score Showing Yearly Bar Chart fy20fy25 with Scores 32 28 21 16 13 11 green Fy25 Bar

Beneish M-Score: The 8-Variable Forensic Model That Caught Enron Three Years Before Bankruptcy

The Beneish M-Score is the 8-variable forensic-accounting model published in 1999 that flagged Enron in 1998 — three years before bankruptcy. Learn how to compute it from any Indian annual report, and see why Titan Biotech FY25's 103% CFO/Operating Profit, ₹3 Cr borrowings, ₹7.78 Cr contingent liabilities and 14 board meetings sit deep in the 'unlikely manipulator' zone.

May 3, 2026

Hero Section with Title the Twenty punch card Rule and a Four color Grid Labeled Trader gray Compounder green Drift light Gray Speculator orange

The Twenty-Punch-Card Rule: Warren Buffett’s Lifetime-Scarcity Discipline for Indian Value Investors

Buffett's twenty-slot punch card forces selectivity, patience and conviction in a single mental model. Titan Biotech's FY25 audited numbers — debt-to-equity 0.02x, ~16.9% RoCE, 103% CFO/operating profit, 55.87% promoter holding — illustrate the discipline.